Lack of skeletal radiographic changes during short-term etretinate therapy for psoriasis.
We prospectively analyzed radiographic skeletal surveys of eight patients who received etretinate therapy for psoriasis at doses ranging from 0.5 to 1.2 mg/kg/day for 6-18 months. Although subtle skeletal changes could have been obscured by some of our patients' other radiographic abnormalities, no bony changes that could be attributed to etretinate were detected in any of these patients.
Gilbert
M
M
Ellis
C N
CN
Voorhees
J J
JJ
D000328:Adult; D000368:Aged; D001842:Bone and Bones / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000473:pathology; D002114:Calcinosis / Q000139:chemically induced; D005050:Etretinate / Q000009:adverse effects*; D005260:Female; D006680:HLA Antigens / Q000032:analysis; D006801:Humans; D006984:Hypertrophy; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D011859:Radiography; D013997:Time Factors
D006680:HLA Antigens; D005050:Etretinate